The complement attack phase: control of lysis and non-lethal effects of C5b-9
- 31 October 1992
- journal article
- review article
- Published by Elsevier in Immunopharmacology
- Vol. 24 (2) , 107-117
- https://doi.org/10.1016/0162-3109(92)90017-7
Abstract
No abstract availableThis publication has 75 references indexed in Scilit:
- The control of homologous lysisImmunology Today, 1991
- Phosphatidylinositol membrane anchors and T-cell activationImmunology Today, 1991
- Complement in Inflammation: Induction of Nephritides and Progress to ChronicityInternational Archives of Allergy and Immunology, 1991
- Deficiency of glycosyl-phosphatidylinositol anchored proteins on paroxysmal nocturnal haemoglobinuria (PNH) neutrophils and monocytes: heterogeneous deficiency of decay-accelerating factor (DAF) and CD16 on PNH neutrophilsBritish Journal of Haematology, 1990
- H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complementCellular Immunology, 1990
- Terminal component of complement C9 in CSF and plasma of patients with MS and aseptic meningitisActa Neurologica Scandinavica, 1989
- Deposition of Terminal C5b–9 Complement Complexes on Erythrocytes and Leukocytes during Cardiopulmonary BypassNew England Journal of Medicine, 1988
- Activation of the human terminal complement pathway in atherosclerosisClinical Immunology and Immunopathology, 1987
- Inhibition of complement by a substance isolated from human erythrocytes — I: Extraction from human erythrocyte stromataImmunochemistry, 1969
- Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serumImmunochemistry, 1966